Difference between revisions of "Fludarabine (Fludara)"

Revision as of 22:11, 5 March 2014

General information

Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.^[1]^[2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

4/18/1991: Initial FDA approval

Also known as

Beneflur, FAMP, Fludarabine Phosphate, Fludara Lyophilisat, Oforta, Trav Fludarabine.

References

[insert-1] 1.0 ^1.1 Fludarabine (Fludara) package insert

[2] Fludarabine (Fludara) package insert (locally hosted backup)

[3] Fludarabine (Fludara) patient drug information (Chemocare)

[4] Fludarabine (Fludara) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 33: / Line 33: @@
 [[Category:DNA synthesis inhibitors]]
 [[Category:Nucleic acid analogs]]
+[[Category:Antimetabolites]]
+[[Category:Purine analogues]]
 [[Category:Acute myeloid leukemia medications]]
 [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]]